1921
Volume 95, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

The aim of this study was to evaluate the effectiveness of benznidazole nanoparticles (BNZ-nps) on trypomastigote forms and on intracellular infection in mammalian cells and primary cardiac myocyte cells. Its effectiveness was also evaluated on acute Nicaragua mice infection. Trypomastigotes from culture were treated with different concentrations of BNZ-nps to determine the drug concentration that lyses 50% of trypomastigotes (LC). Infected mammalian cells were incubated with different concentrations of BNZ-nps to determine the percentage of amastigote inhibition. CH/HeN mice with lethal acute infection were treated with 10, 25, and 50 mg/kg/day of BNZ-nps for 30 and 15 days to control the survival rate of animals. BNZ-nps having a mean particle size of 63.3 nm, a size distribution of 3.35, and a zeta potential of −18.30 were successfully prepared using poloxamer 188 as a stabilizer. BNZ-nps 25 and 50 μg/mL showed no significant differences in the percentage of inhibition of infected mammalian cells. Infected mice treated with BNZ-nps (50, 25, and 10 mg/kg/day) for 30 days and with BNZ-nps (50 and 25 mg/kg/day) for 15 days presented a 100% survival, whereas the animals treated with 10 mg/kg/day for 15 days of BNZ-nps showed a 70% survival rate. The results obtained demonstrate, for the first time, that benznidazole nanoparticles are a useful and attractive approach to treat Chagas disease in infected mice.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0889
2016-08-03
2017-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/2/388.html?itemId=/content/journals/10.4269/ajtmh.15-0889&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2013. Sustaining the Drive to Overcome the Global Impact of Neglected Tropical Diseases. Second WHO Report on Neglected Tropical Diseases. Geneva, Switzerland: WHO. Available at: http://www.who.int/neglected_diseases/9789241564540/en/. Accessed December 10, 2014.
  2. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C, , 1998. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 59: 526529.
  3. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R, , 2009. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 64: 11391147.[Crossref]
  4. Bonney KM, , 2014. Chagas disease in the 21st century: a public health success or an emerging threat? Parasite 21: 110.[Crossref]
  5. Leonardi D, Salomon CJ, , 2013. Unexpected performance of physical mixtures over solid dispersions on the dissolution behavior of benznidazole from tablets. J Pharm Sci 102: 10161023.[Crossref]
  6. Salomon CJ, , 2011. First century of Chagas' disease: an overview on novel approaches to nifurtimox and benznidazole delivery systems. J Pharm Sci 101: 888894.[Crossref]
  7. Morilla MJ, Romero EL, , 2015. Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. Nanomedicine (Lond) 10: 465481.[Crossref]
  8. Grosso NL, Bua J, Perrone AE, Gonzalez MN, Bustos PL, Postan M, Fichera LE, , 2010. Trypanosoma cruzi: biological characterization of a Trypanosoma cruzi isolate from an endemic area and its susceptibility to conventional drugs. Exp Parasitol 126: 239244.[Crossref]
  9. Grosso NL, López Alarcón M, Bua J, Laucella SA, Riarte A, Fichera LE, , 2013. Combined treatment with benznidazole and allopurinol in mice infected with a virulent Trypanosoma cruzi isolate from Nicaragua. Parasitology 140: 12251233.[Crossref]
  10. Sladowski D, Steer SJ, Clothier RH, Balls M, , 1993. An improved MTT assay. J Immunol Methods 4: 203207.[Crossref]
  11. Veiga-Santos P, Pelizzaro-Rocha KJ, Santos AO, Ueda-Nakamura T, Dias Filho BP, Silva SO, Sudatti DB, Bianco EM, Pereira RC, Nakamura CV, , 2010. In vitro anti-trypanosomal activity of elatol isolated from red seaweed Laurencia dendroidea . Parasitology 137: 16611670.[Crossref]
  12. Brener Z, , 1962. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi . Rev Inst Med Trop Sao Paulo 4: 389396.
  13. Ellingsen O, Davidoff AJ, Prasad SK, Berger HJ, Springhorn JP, Marsh JD, Kelly RA, Smith TW, , 1993. Adult rat ventricular myocytes cultured in defined medium: phenotype and electromechanical function. Am J Physiol 265: H747H754.
  14. Fichera LE, Albareda MC, Laucella SA, Postam M, , 2004. Intracellular growth of Trypanosoma cruzi in cardiac myocytes is inhibited by cytokine-induced nitric oxide release. Infect Immun 70: 359363.[Crossref]
  15. Van Eerdenbrugh B, Van den Mooter G, Augustijns P, , 2008. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 364: 6475.[Crossref]
  16. Kroll A, Pillukat MH, Hahn D, Schnekenburger J, , 2009. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur J Pharm Biopharm 72: 370377.[Crossref]
  17. Morilla M, Prieto MJ, Romero EL, , 2005. Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components? Mem Inst Oswaldo Cruz 100: 213219.[Crossref]
  18. Liu F, Park JY, Zhang Y, Conwell C, Liu Y, Bathula SR, Huang L, , 2010. Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci 99: 35423551.[Crossref]
  19. Toledo MJO, Bahia MT, Veloso VM, Carneiro CM, Machado-Coelho GLL, Alves CF, Martins HR, Cruz RE, Tafuri WL, Lana M, , 2004. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes. J Antimicrob Chemother 53: 10451053.[Crossref]
  20. Palmeiro-Roldán R, Fonseca-Berzal C, Gómez-Barrio A, Arán VJ, Escario JA, Torrado-Durán S, Torrado-Santiago S, , 2014. Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease. Int J Pharm 472: 110117.[Crossref]
  21. Leonardi D, Bombardiere ME, Salomon CJ, , 2013. Effects of benznidazole:cyclodextrin complexes on the drug bioavailability upon oral administration to rats. Int J Biol Macromol 62: 543548.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0889
Loading
/content/journals/10.4269/ajtmh.15-0889
Loading

Data & Media loading...

  • Received : 10 Dec 2015
  • Accepted : 18 Apr 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error